Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vincent

Showing results (951-960 of 968) with videos related to

Pageof 97
Sort By:
Bone Marrow Transplantation|July 11, 2018
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statementWilson I Gonsalves, Francis K Buadi, Sikander Ailawadhi, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 19, 2013
Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic lossMaria Talantova, Sara Sanz-Blasco, Xiaofei Zhang, et al.
Mayo Clinic Proceedings|June 5, 2021
Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 UpdateEli Muchtar, Angela Dispenzieri, Morie A Gertz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2025
Genomics Define Malignant Transformation in Myeloma Precursor ConditionsFrancesco Maura, P Leif Bergsagel, Bachisio Ziccheddu, et al.
American Journal of Hematology|December 10, 2019
Impact of MYD88<sup>L265P</sup> mutation status on histological transformation of Waldenström MacroglobulinemiaSaurabh Zanwar, Jithma P Abeykoon, Eric Durot, et al.
Mayo Clinic Proceedings|August 13, 2010
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelinesStephen M Ansell, Robert A Kyle, Craig B Reeder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2025
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple MyelomaHervé Avet-Loiseau, Faith E Davies, Mehmet K Samur, et al.
Blood Advances|April 22, 2026
A multi-center study of progression-risk and outcomes in solitary bone plasmacytoma with and without marrow involvementKenneth Jc Lim, Maximilian Johannes Steinhardt, Matthew J Rees, et al.
JAMA Oncology|January 6, 2017
Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016Prashant Kapoor, Stephen M Ansell, Rafael Fonseca, et al.
Nature|March 25, 2011
Initial genome sequencing and analysis of multiple myelomaMichael A Chapman, Michael S Lawrence, Jonathan J Keats, et al.
Pageof 97

Showing results (951-960 of 968) with videos related to

Sort By:
Pageof 97
Bone Marrow Transplantation|July 11, 2018
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statementWilson I Gonsalves, Francis K Buadi, Sikander Ailawadhi, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 19, 2013
Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic lossMaria Talantova, Sara Sanz-Blasco, Xiaofei Zhang, et al.
Mayo Clinic Proceedings|June 5, 2021
Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 UpdateEli Muchtar, Angela Dispenzieri, Morie A Gertz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2025
Genomics Define Malignant Transformation in Myeloma Precursor ConditionsFrancesco Maura, P Leif Bergsagel, Bachisio Ziccheddu, et al.
American Journal of Hematology|December 10, 2019
Impact of MYD88<sup>L265P</sup> mutation status on histological transformation of Waldenström MacroglobulinemiaSaurabh Zanwar, Jithma P Abeykoon, Eric Durot, et al.
Mayo Clinic Proceedings|August 13, 2010
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelinesStephen M Ansell, Robert A Kyle, Craig B Reeder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2025
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple MyelomaHervé Avet-Loiseau, Faith E Davies, Mehmet K Samur, et al.
Blood Advances|April 22, 2026
A multi-center study of progression-risk and outcomes in solitary bone plasmacytoma with and without marrow involvementKenneth Jc Lim, Maximilian Johannes Steinhardt, Matthew J Rees, et al.
JAMA Oncology|January 6, 2017
Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016Prashant Kapoor, Stephen M Ansell, Rafael Fonseca, et al.
Nature|March 25, 2011
Initial genome sequencing and analysis of multiple myelomaMichael A Chapman, Michael S Lawrence, Jonathan J Keats, et al.
Pageof 97